Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Yunju Bae"'
Autor:
Miwa Haranaka, Takanori Tanaka, SungHyun Kim, YunJu Bae, DaBee Jeon, EunJin Choi, JungBin Cha, SangMi Lee, Yoichiro Ogama
Publikováno v:
Immunotherapy. 15:149-161
Aim: Comparing pharmacokinetics and safety of CT-P17 and EU-approved reference adalimumab (EU–adalimumab) in Japan. Materials & methods: Double-blind, parallel-group phase I trial at three hospitals. Healthy Japanese adults were randomized (1:1) to
Autor:
Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, Min Kyu Park, Jun Gi Hwang, Min-Gul Kim, Hyewon Chung, JongLyul Ghim, Jae-Yong Chung, Josef S. Smolen, Gerd R. Burmester, SungHyun Kim, YunJu Bae, DaBee Jeon, JaeKyoung Yoo, GoEun Yang, JiHun Bae, Edward Keystone
CT-P47 is a candidate tocilizumab biosimilar. This study assessed the pharmacokinetic (PK) equivalence of CT-P47 and European Union-approved reference tocilizumab (EU-tocilizumab) in healthy Asian adults. This double-blind, multicenter, parallel-grou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdd8a4601b90bb7c358850b917d65789
Publikováno v:
Korean Association for Educational Information and Media. 26:853-878
Autor:
Yunju Bae, Min Young Doo
Publikováno v:
Journal of Education & Culture. 25:319-339
Autor:
Jaebong Lim, Yunju Baek
Publikováno v:
IEEE Access, Vol 11, Pp 100540-100553 (2023)
Spoken keyword spotting, which is characterized by simplicity and low latency, has been widely used in consumer electronics to facilitate always-on voice interfaces. Small-footprint keyword spotting based on tiny convolutional neural networks can be
Externí odkaz:
https://doaj.org/article/b45c1752e39a4b74a952717ea34f9b51
Autor:
Michinori Ogura, Wojciech Jurczak, Bertrand Coiffier, Gayane Tumyan, Jose Mario Mariz, Sungyoung Lee, Leslie Popplewell, Eduardo Yanez Ruiz, Seok-Goo Cho, Jin Seok Kim, Hideyuki Nakazawa, Larry W. Kwak, Christian Buske, Juan-Manuel Sancho, A. Martínez, Won Seog Kim, Sang Joon Lee, Olga Samoilova, Edvard Zhavrid, Marek Trneny, Junji Suzumiya, Yunju Bae, Anne Lennard, Nikolai Ilyin
Publikováno v:
Blood. 132:1596-1596
Background: CT-P10 is the first biosimilar to innovator rituximab (RTX) approved for all indications by the European Medicines Agency. The pharmacokinetics (PK) equivalence and non-inferior efficacy of CT-P10 compared with RTX in patients with newly
Publikováno v:
Toxicology and Applied Pharmacology. 254:56-64
A great number of people are suffering from allergic inflammatory diseases such as asthma, atopic dermatitis, and sinusitis. Therefore discovery of drugs for the treatment of these diseases is an important subject in human health. Chrysin (5,7-dihydr
Autor:
Hee-Young Son, Thoudam S.K. Singh, Mi-Sun Kim, Sang-Hyun Kim, Seung-Bin Park, Soyoung Lee, Hong-In Shin, Eun-Ju Choi, Moon-Chang Baek, Tae Seok Kang, Seung Jun Kwack, Yunju Bae
Publikováno v:
Immunopharmacology and Immunotoxicology. 32:277-283
Mercuric sulfide (HgS) is a major component of cinnabar, which has been used as a sedative drug in China for more than 2000 years. Because its toxicological effects are still unclear, we attempted to verify the toxic effects of HgS, focused on liver
Autor:
Mie Jin Lim, Sergio Gutierrez-Ureña, Marek Brzosko, Helena Mikazane, Yeon Ah Lee, Jürgen Braun, Piotr Wiland, Vladimir Kadinov, Yunju Bae, Svitlana Smiyan, HoUng Kim, Suyeon Kim, Pedro Miranda, Carlos Abud-Mendoza, Sang Joon Lee, Won Park, Dae Hyun Yoo
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTo investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS).MethodsThis open-label extension study recruited p
Autor:
Bertrand Coiffier, Dzhelil Osmanov, Mariana Vasilica, Won Seog Kim, Aliaksandr Prokharau, Sungyoung Lee, Juan-Manuel Sancho, Christian Buske, Jin Seok Kim, Sang-Joon Lee, Wojciech Jurczak, Edvard Javrid, Larry W. Kwak, Rajnish Nagarkar, Jose Angel Hernandez Rivas, Michinori Ogura, Yunju Bae
Publikováno v:
Journal of Clinical Oncology. 35:7532-7532
7532 Background: CT-P10 is a biosimilar candidate to the innovator rituximab (RTX). In patients with rheumatoid arthritis, CT-P10 has demonstrated equivalence in pharmacokinetics (PK) and efficacy (Yoo, ACR 2016). This study aimed to demonstrate non-